Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan » 07:40
08/12/22
08/12
07:40
08/12/22
07:40
SNY

Sanofi

$43.46 /

-1.74 (-3.85%)

, GSK

GSK plc

$35.75 /

-2.57 (-6.71%)

, HLN

Haleon

$6.29 /

-0.22 (-3.38%)

, PFE

Pfizer

$48.31 /

-1.62 (-3.24%)

JPMorgan analysts Richard…

JPMorgan analysts Richard Vosser and James Gordon note that shares of GSK plc (GSK), Sanofi (SNY), Haleon (HLN) and Pfizer (PFE) have lost a combined market cap of $44B week to date, which they attribute largely to concerns around potential liabilities related to Zantac litigation. They believe the magnitude of this week's market cap hit "likely exceeds even a worst-case scenario" and also believe the market has not fairly attributed any potential Zantac liability between the various companies involved, the analysts tell investors. GSK is likely to have the clearest evidence linking Zantac use to individual named patients given that it sold the product on a prescription basis from 1983, but they still see this week's $12B hit to the company's market cap as a "potential over-reaction." Still, Vosser and Gordon state in their note that they don't see the GSK overhang shifting ahead of the first bellweather case being heard this coming February. In contrast, they believe it is possible that Sanofi may not be liable for any litigation damages given the company's indemnification agreement with Boehringer that is currently under arbitration. Even in the event Sanofi is not fully indemnified, their exposure via OTC sales would likely be lower than GSK and the company's $16.5B loss in market cap this week means an "overly bearish Zantac outlook is now likely priced in," the analysts said. The firm has an Overweight rating on Sanofi shares and a Neutral rating on GSK.

ShowHide Related Items >><<
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

SNY Sanofi
$43.46 /

-1.74 (-3.85%)

08/12/22 Deutsche Bank
Sanofi upgraded to Hold from Sell at Deutsche Bank
08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 UBS
Sanofi downgraded to Neutral from Buy at UBS
GSK GSK plc
$35.75 /

-2.57 (-6.71%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
HLN Haleon
$6.29 /

-0.22 (-3.38%)

07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
07/25/22 Goldman Sachs
Haleon initiated with a Buy at Goldman Sachs (last week)
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

Hot Stocks
Pfizer reports 'positive' results from Phase 3 study of 20vPnC » 06:47
08/12/22
08/12
06:47
08/12/22
06:47
PFE

Pfizer

$48.31 /

-1.62 (-3.24%)

Pfizer announced positive…

Pfizer announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate, 20vPnC, for the prevention of invasive pneumococcal disease caused by the 20 Streptococcus pneumoniae serotypes contained in the vaccine for the pediatric population. The study had two co-primary objectives, associated with immunogenicity responses one month after the third and fourth doses of the four-dose vaccination series, respectively: non-inferiority of the percentage of participants with predefined serotype-specific immunoglobin G concentrations after Dose 3 and NI of IgG geometric mean concentrations after Dose 4. All 20 serotypes met the co-primary objective of NI of IgG GMCs after Dose 4. Fourteen of the 20 serotypes met the co-primary objective of NI of the percentage of participants with predefined IgG levels after Dose 3 (two serotypes missed by a wider margin while four narrowly missed), and all serotypes met noninferiority for the key secondary objective of IgG GMCs after Dose 3. All 20 serotypes elicited robust functional responses and increases in antibody responses after Dose 4, with the totality of data supporting the potential benefit of all serotypes in this 20-valent vaccine candidate. Overall, the safety profile of the 20vPnC candidate was consistent with Prevnar 13 given in the same schedule. A similar percentage of infants receiving either vaccine experienced local reactions (pain at the injection site, redness, and swelling), fever, and other systemic events. The study also met non-inferiority objectives for responses to co-administered routinely used pediatric vaccines. Based on the totality of positive safety and immunogenicity data, Pfizer plans to submit a supplemental Biologics License Application by the end of this year, subject to discussions with the U.S. FDA. Pfizer will seek to present and publish outcomes from this clinical trial at a future date once safety and immunogenicity data have been fully analyzed. Additional top-line results from other pediatric 20vPnC clinical trials are expected to read out in the second half of 2022, with discussions with other regulatory bodies planned once those pivotal data become available.

ShowHide Related Items >><<
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

Thursday
Hot Stocks
Haleon says it is not a party to any Zantac claims » 17:22
08/11/22
08/11
17:22
08/11/22
17:22
HLN

Haleon

$6.29 /

-0.22 (-3.38%)

, GSK

GSK plc

$35.75 /

-2.57 (-6.71%)

, PFE

Pfizer

$48.31 /

-1.62 (-3.24%)

Haleon (HLN) released a…

Haleon (HLN) released a statement noting the recent volatility in its share price and is aware of market speculation on Haleon's potential liability in respect of Zantac product liability litigation. "Haleon is not aware of any material developments in relation to the Zantac litigation since the Haleon prospectus was issued on 1 June 2022," the company said. "Haleon is not a party to any of the Zantac claims. Haleon never marketed Zantac in any form in the U.S. Haleon is not primarily liable for any OTC or prescription claims. To the extent GSK (GSK) and/or Pfizer (PFE) are held liable in respect of OTC Zantac during the periods outlined below, Haleon may be required to indemnify GSK and/or Pfizer, only if the following conditions are met: GSK and/or Pfizer are unable to recover in respect of OTC Zantac from any third parties who are ahead of Haleon and who have given indemnities under previous transfers of rights to OTC Zantac; and Haleon is determined to be liable under the indemnification provisions among Haleon, Pfizer and GSK."

ShowHide Related Items >><<
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
07/25/22 Goldman Sachs
Haleon initiated with a Buy at Goldman Sachs (last week)
GSK GSK plc
$35.75 /

-2.57 (-6.71%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

Recommendations
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan » 14:50
08/11/22
08/11
14:50
08/11/22
14:50
PRGO

Perrigo

$41.26 /

-0.475 (-1.14%)

, PFE

Pfizer

$48.11 /

-1.82 (-3.65%)

, SNY

Sanofi

$43.79 /

-1.41 (-3.12%)

, GSK

GSK plc

$35.32 /

-2.995 (-7.82%)

, HLN

Haleon

$6.24 /

-0.275 (-4.22%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott notes the refocus on Zantac liability that has emerged this week, and driven shares of GSK plc (GSK) and Sanofi (SNY) lower, and says he has been getting a number of questions on potential implications within his coverage, namely regarding Perrigo (PRGO) and Pfizer (PFE). As a store brand manufacturer, Perrigo's preemption and HatchWaxman defenses are "very strong," the company has been dismissed from one federal MDL litigation and is not named in the upcoming Madison IL trial, so he does not see Zantac litigation as a significant risk for Perrigo, Schott tells investors. Pfizer sold its rights to Zantac in 2006 and appears to be "at least partially indemnified" from any liability here by Haleon (HLN), said Schott, who contends that the company's loss of about $10B in market cap on this issue "seems overdone" relative to Pfizer's potential exposure. Schott has an Overweight rating on Perrigo shares and a Neutral rating on Pfizer.

ShowHide Related Items >><<
SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

HLN Haleon
$6.24 /

-0.275 (-4.22%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

05/31/22 Jefferies
Perrigo transferred with a Buy at Jefferies
11/11/21 Raymond James
Perrigo price target lowered to $55 from $59 at Raymond James
10/14/21
Fly Intel: Top five analyst upgrades
10/14/21 Raymond James
Raymond James upgrades Perrigo to buy on HRA deal, tax settlement
PFE Pfizer
$48.11 /

-1.82 (-3.65%)

08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
SNY Sanofi
$43.79 /

-1.41 (-3.12%)

08/09/22 UBS
Sanofi downgraded to Neutral from Buy at UBS
08/05/22 Stifel
Sanofi price target raised to EUR 119 from EUR 115 at Stifel
07/29/22 JPMorgan
Sanofi price target raised to EUR 115 from EUR 105 at JPMorgan
GSK GSK plc
$35.32 /

-2.995 (-7.82%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
08/05/22 Morgan Stanley
GSK plc resumed with an Equal Weight at Morgan Stanley
HLN Haleon
$6.24 /

-0.275 (-4.22%)

07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
07/25/22 Goldman Sachs
Haleon initiated with a Buy at Goldman Sachs (last week)
07/25/22 Credit Suisse
Haleon initiated with an Outperform at Credit Suisse (last week)
SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

HLN Haleon
$6.24 /

-0.275 (-4.22%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

HLN Haleon
$6.24 /

-0.275 (-4.22%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

On The Fly
Renewed Zantac litigation concerns sinking these big-cap drugmakers » 13:35
08/11/22
08/11
13:35
08/11/22
13:35
GSK

GSK plc

$34.82 /

-3.495 (-9.12%)

, SNY

Sanofi

$43.47 /

-1.73 (-3.83%)

, HLN

Haleon

$6.09 /

-0.42 (-6.45%)

, PFE

Pfizer

$48.21 /

-1.72 (-3.44%)

Shares of GSK plc (GSK),…

ShowHide Related Items >><<
SNY Sanofi
$43.47 /

-1.73 (-3.83%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

HLN Haleon
$6.09 /

-0.42 (-6.45%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

08/12/22 JPMorgan
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan
08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
SNY Sanofi
$43.47 /

-1.73 (-3.83%)

08/12/22 Deutsche Bank
Deutsche Bank raises Sanofi to Hold, calls Zantac 'knee-jerk' reaction overdone
08/12/22 Deutsche Bank
Sanofi upgraded to Hold from Sell at Deutsche Bank
HLN Haleon
$6.09 /

-0.42 (-6.45%)

07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
PFE Pfizer
$48.21 /

-1.72 (-3.44%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
SNY Sanofi
$43.47 /

-1.73 (-3.83%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

SNY Sanofi
$43.47 /

-1.73 (-3.83%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

HLN Haleon
$6.09 /

-0.42 (-6.45%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

HLN Haleon
$6.09 /

-0.42 (-6.45%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

Hot Stocks
Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation » 12:30
08/11/22
08/11
12:30
08/11/22
12:30
SNY

Sanofi

$43.24 /

-1.965 (-4.35%)

, GSK

GSK plc

$34.51 /

-3.805 (-9.93%)

, PFE

Pfizer

$48.08 /

-1.85 (-3.71%)

Sanofi issued the…

Sanofi issued the following media update: "In response to the recent highly speculative news flow regarding the U.S. Zantac litigation at a time when there have not been any material developments, Sanofi remains confident in its legal defenses and wishes to make the following statement, consistent with what has been disclosed previously: On September 13, 2019, FDA issued a statement alerting the public that some ranitidine medicines, including over-the-counter Zantac, contained a nitrosamine impurity called N-nitrosodimethylamine, or NDMA, at low levels. NDMA is a known environmental contaminant found in drinking water, soil, and common foods, including meats, dairy products, and vegetables. People are routinely exposed to small amounts of NDMA every day. FDA subsequently announced that its preliminary testing showed NDMA levels exceeded FDA's allowable limit in some of the samples it tested. Upon receipt of this information, however, Sanofi quickly mobilized, ran additional confirmatory testing, and out of an abundance of caution issued a voluntary recall of all ranitidine Zantac OTC products in the U.S. and Canada. Since 2019, the medical, scientific, and regulatory communities have extensively evaluated the safety of Zantac's active ingredient ranitidine, and the data shows there is no evidence of consumer harm from real-world use of Zantac. Over time, both FDA and the European Medicines Agency have evaluated the available data and found no evidence that ranitidine causes cancer. Regardless of the scientific evidence, within days of FDA's 2019 announcement, purported class actions and personal injury lawsuits were filed in US courts, seeking economic damages or alleging that Zantac caused various cancers. However, given that Sanofi acted responsibly at all times and the lack of scientific support for plaintiffs' claims, Sanofi is fully confident in its defenses to the litigation. Sanofi stands by the safety of the medicine today. Importantly, Sanofi acquired the OTC rights to Zantac less than three years before these lawsuits commenced, and after the medicine had been on the market for more than 35 years. In addition to Sanofi, three other companies that marketed Rx and/or branded OTC Zantac over time -- GSK, Pfizer, and Boehringer Ingelheim -- are also named as defendants in these actions. Other additionally named defendants have included dozens of generic manufacturers, retailers, and pharmaceutical distributors. The first trial that may involve Sanofi as a defendant is currently scheduled for February 2023 as a part of the California state court proceedings. Sanofi is not a defendant in many of the other cases currently set for trial. Sanofi's sales of Zantac account for only a very small percentage of the product's total sales over the 35+ years that Rx and OTC Zantac was available. Potential historical brand liability was not all passed to Sanofi upon its acquisition of Zantac. Sanofi acquired the marketing rights to Zantac from Boehringer Ingelheim in 2017. Boehringer Ingelheim continued to manufacture Zantac during the period Sanofi marketed the product. As to the respective indemnification rights and obligations of Sanofi in the context of its acquisition of the product from Boehringer Ingelheim, those obligations are being disputed between the parties in the arbitration. The arbitration award is expected to be rendered around year-end 2022. Regardless of the arbitration outcome, the legal defenses in the US litigation are strong. As of August 1, 2022, Sanofi was aware of approximately 2,850 personal injury plaintiffs across both state and federal jurisdictions with filed cases naming Sanofi in addition to other defendants. When factoring in additional Zantac cases that do not involve Sanofi, Sanofi is aware of approximately 3,450 total personal injury plaintiffs across all jurisdictions. There are other potential personal injury claimants who, in lieu of filing a court case, have instead joined a registry of "unfiled" claims established by the federal MDL court. The data on these potential cases remain preliminary and unverified and subject to change. It remains unknown how many unfiled claimants who have participated in the Registry may file suit, or whether any of those claimants will name Sanofi as a defendant in any such suits. Over time, the number of unfiled claims alleging either Rx and/or OTC use and implicating a variety of defendants in these actions has exceeded 150,000 - a significant number of these claims, however, do not implicate Sanofi. The science does not support the plaintiffs' claims in this litigation. There is no reliable evidence that Zantac causes any of the alleged injuries under real-world conditions, and Sanofi remains fully confident in its defenses. Given the strength of our case and the uncertainty of future proceedings no contingencies have been established." Reference Link

ShowHide Related Items >><<
SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

SNY Sanofi
$43.24 /

-1.965 (-4.35%)

08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 UBS
Sanofi downgraded to Neutral from Buy at UBS
08/05/22 Stifel
Sanofi price target raised to EUR 119 from EUR 115 at Stifel
07/29/22 JPMorgan
Sanofi price target raised to EUR 115 from EUR 105 at JPMorgan
GSK GSK plc
$34.51 /

-3.805 (-9.93%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
08/05/22 Morgan Stanley
GSK plc resumed with an Equal Weight at Morgan Stanley
PFE Pfizer
$48.08 /

-1.85 (-3.71%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

Options
Pfizer call volume above normal and directionally bullish » 11:05
08/11/22
08/11
11:05
08/11/22
11:05
PFE

Pfizer

$48.72 /

-1.21 (-2.42%)

Bullish option flow…

Bullish option flow detected in Pfizer with 55,383 calls trading, 3x expected, and implied vol increasing almost 2 points to 25.83%. Nov-22 50 calls and 9/9 weekly 46 puts are the most active options, with total volume in those strikes near 30,200 contracts. The Put/Call Ratio is 0.41. Earnings are expected on November 1st.

ShowHide Related Items >><<
PFE Pfizer
$48.72 /

-1.21 (-2.42%)

PFE Pfizer
$48.72 /

-1.21 (-2.42%)

08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
PFE Pfizer
$48.72 /

-1.21 (-2.42%)

PFE Pfizer
$48.72 /

-1.21 (-2.42%)

PFE Pfizer
$48.72 /

-1.21 (-2.42%)

PFE Pfizer
$48.72 /

-1.21 (-2.42%)

Recommendations
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank » 08:34
08/11/22
08/11
08:34
08/11/22
08:34
GSK

GSK plc

/

+

, HLN

Haleon

$6.51 /

-0.605 (-8.50%)

, PFE

Pfizer

$49.93 /

+0.16 (+0.32%)

, SNY

Sanofi

$45.20 /

-3.48 (-7.15%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis said lawsuits related to the NDMA impurity found in the legacy ranitidine-based version of Zantac that was withdrawn from the market in 2019 is a topic that "is not new," but one that has "arrived in investor consciousness in recent days" ahead of "imminently pending cases," including an Illinois case that is scheduled for August 22 and "key bellweather trials" in California starting early in 2023. He doesn't think the evidence "points to this as another glyphosate," but it is very possible a liability of "some billions of dollars in magnitude" may be incurred, said Papadakis, who thinks negative headlines from the pending cases is likely to act as a short-term headwind for investors' sentiment on both GSK plc (GSK) and Sanofi (SNY), if it has not already. It appears to him "very possible" that parties including GSK/Haleon (HLN), Pfizer (PFE), Boehringer Ingelheim and Sanofi may incur the risk of some degree of shared liability, with "the only real questions being what that magnitude of liability may be and when the market feels it can get a handle on it," said Papadakis, who estimates that precedents would suggest an implied shared liability from the present caseload in the $5B-$10B range.

ShowHide Related Items >><<
SNY Sanofi
$45.20 /

-3.48 (-7.15%)

PFE Pfizer
$49.93 /

+0.16 (+0.32%)

HLN Haleon
$6.51 /

-0.605 (-8.50%)

GSK GSK plc
/

+

GSK GSK plc
/

+

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
08/05/22 Morgan Stanley
GSK plc resumed with an Equal Weight at Morgan Stanley
07/21/22 Citi
GSK plc resumed with a Neutral at Citi
HLN Haleon
$6.51 /

-0.605 (-8.50%)

07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
07/25/22 Goldman Sachs
Haleon initiated with a Buy at Goldman Sachs (last week)
07/25/22 Credit Suisse
Haleon initiated with an Outperform at Credit Suisse (last week)
07/25/22 BofA
Haleon initiated with a Buy at BofA (last week)
PFE Pfizer
$49.93 /

+0.16 (+0.32%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
08/08/22 Stifel
Global Blood Therapeutics downgraded to Hold from Buy at Stifel
SNY Sanofi
$45.20 /

-3.48 (-7.15%)

08/09/22 UBS
Sanofi downgraded to Neutral from Buy at UBS
08/05/22 Stifel
Sanofi price target raised to EUR 119 from EUR 115 at Stifel
07/29/22 JPMorgan
Sanofi price target raised to EUR 115 from EUR 105 at JPMorgan
07/29/22 Deutsche Bank
Sanofi price target raised to EUR 90 from EUR 85 at Deutsche Bank
SNY Sanofi
$45.20 /

-3.48 (-7.15%)

PFE Pfizer
$49.93 /

+0.16 (+0.32%)

GSK GSK plc
/

+

PFE Pfizer
$49.93 /

+0.16 (+0.32%)

GSK GSK plc
/

+

SNY Sanofi
$45.20 /

-3.48 (-7.15%)

PFE Pfizer
$49.93 /

+0.16 (+0.32%)

HLN Haleon
$6.51 /

-0.605 (-8.50%)

GSK GSK plc
/

+

PFE Pfizer
$49.93 /

+0.16 (+0.32%)

HLN Haleon
$6.51 /

-0.605 (-8.50%)

GSK GSK plc
/

+

Tuesday
Conference/Events
JPMorgan biotech analysts to hold analyst/industry conference call » 12:45
08/09/22
08/09
12:45
08/09/22
12:45
ALNY

Alnylam

$228.31 /

-2.55 (-1.10%)

, IONS

Ionis Pharmaceuticals

$43.70 /

-2.01 (-4.40%)

, BBIO

BridgeBio

$11.00 /

-0.91 (-7.64%)

, PFE

Pfizer

$49.90 /

+0.345 (+0.70%)

Biotech Analysts, along…

Biotech Analysts, along with Key Opinion Leader, Dr. Rodney Falk of Brigham & Women's Hospital, discuss ALNY/IONS/BBIO/PFE and provide their perspectives post APOLLO-B results on an Analyst/Industry conference call to be held on August 9 at 1 pm. Webcast Link

ShowHide Related Items >><<
PFE Pfizer
$49.90 /

+0.345 (+0.70%)

IONS Ionis Pharmaceuticals
$43.70 /

-2.01 (-4.40%)

BBIO BridgeBio
$11.00 /

-0.91 (-7.64%)

ALNY Alnylam
$228.31 /

-2.55 (-1.10%)

ALNY Alnylam
$228.31 /

-2.55 (-1.10%)

08/05/22 JPMorgan
BridgeBio selloff on Alnylam readout overdone, says JPMorgan
08/04/22 Citi
Alnylam price target raised to $280 from $206 at Citi
08/03/22 Stifel
Alnylam price target raised to $247 from $215 at Stifel
08/03/22 Chardan
Alnylam price target raised to $250 from $200 at Chardan
IONS Ionis Pharmaceuticals
$43.70 /

-2.01 (-4.40%)

07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
06/23/22 Citi
Citi adds AutoZone, Thermo Fisher, Ionis to 'Focus List'
BBIO BridgeBio
$11.00 /

-0.91 (-7.64%)

07/26/22 Piper Sandler
BioMarin competitor BridgeBio data falls short, says Piper Sandler
03/16/22 H.C. Wainwright
BridgeBio price target lowered to $22 from $24 at H.C. Wainwright
03/11/22 JPMorgan
BridgeBio price target lowered to $18 from $21 at JPMorgan
PFE Pfizer
$49.90 /

+0.345 (+0.70%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
08/08/22 Stifel
Global Blood Therapeutics downgraded to Hold from Buy at Stifel
PFE Pfizer
$49.90 /

+0.345 (+0.70%)

IONS Ionis Pharmaceuticals
$43.70 /

-2.01 (-4.40%)

BBIO BridgeBio
$11.00 /

-0.91 (-7.64%)

ALNY Alnylam
$228.31 /

-2.55 (-1.10%)

PFE Pfizer
$49.90 /

+0.345 (+0.70%)

PFE Pfizer
$49.90 /

+0.345 (+0.70%)

IONS Ionis Pharmaceuticals
$43.70 /

-2.01 (-4.40%)

BBIO BridgeBio
$11.00 /

-0.91 (-7.64%)

ALNY Alnylam
$228.31 /

-2.55 (-1.10%)

PFE Pfizer
$49.90 /

+0.345 (+0.70%)

Conference/Events
JPMorgan biotech analysts to hold analyst/industry conference call » 11:05
08/09/22
08/09
11:05
08/09/22
11:05
ALNY

Alnylam

$229.25 /

-1.61 (-0.70%)

, IONS

Ionis Pharmaceuticals

$44.87 /

-0.84 (-1.84%)

, BBIO

BridgeBio

$11.32 /

-0.59 (-4.95%)

, PFE

Pfizer

$49.77 /

+0.215 (+0.43%)

Biotech Analysts, along…

Biotech Analysts, along with Key Opinion Leader, Dr. Rodney Falk of Brigham & Women's Hospital, discuss ALNY/IONS/BBIO/PFE and provide their perspectives post APOLLO-B results on an Analyst/Industry conference call to be held on August 9 at 1 pm. Webcast Link

ShowHide Related Items >><<
PFE Pfizer
$49.77 /

+0.215 (+0.43%)

IONS Ionis Pharmaceuticals
$44.87 /

-0.84 (-1.84%)

BBIO BridgeBio
$11.32 /

-0.59 (-4.95%)

ALNY Alnylam
$229.25 /

-1.61 (-0.70%)

ALNY Alnylam
$229.25 /

-1.61 (-0.70%)

08/05/22 JPMorgan
BridgeBio selloff on Alnylam readout overdone, says JPMorgan
08/04/22 Citi
Alnylam price target raised to $280 from $206 at Citi
08/03/22 Stifel
Alnylam price target raised to $247 from $215 at Stifel
08/03/22 Chardan
Alnylam price target raised to $250 from $200 at Chardan
IONS Ionis Pharmaceuticals
$44.87 /

-0.84 (-1.84%)

07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
06/23/22 Citi
Citi adds AutoZone, Thermo Fisher, Ionis to 'Focus List'
BBIO BridgeBio
$11.32 /

-0.59 (-4.95%)

07/26/22 Piper Sandler
BioMarin competitor BridgeBio data falls short, says Piper Sandler
03/16/22 H.C. Wainwright
BridgeBio price target lowered to $22 from $24 at H.C. Wainwright
03/11/22 JPMorgan
BridgeBio price target lowered to $18 from $21 at JPMorgan
PFE Pfizer
$49.77 /

+0.215 (+0.43%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
08/08/22 Stifel
Global Blood Therapeutics downgraded to Hold from Buy at Stifel
PFE Pfizer
$49.77 /

+0.215 (+0.43%)

IONS Ionis Pharmaceuticals
$44.87 /

-0.84 (-1.84%)

BBIO BridgeBio
$11.32 /

-0.59 (-4.95%)

ALNY Alnylam
$229.25 /

-1.61 (-0.70%)

PFE Pfizer
$49.77 /

+0.215 (+0.43%)

PFE Pfizer
$49.77 /

+0.215 (+0.43%)

IONS Ionis Pharmaceuticals
$44.87 /

-0.84 (-1.84%)

BBIO BridgeBio
$11.32 /

-0.59 (-4.95%)

ALNY Alnylam
$229.25 /

-1.61 (-0.70%)

PFE Pfizer
$49.77 /

+0.215 (+0.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.